Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 24 of 24 publications.
Skip to main content
Ray KK, Bardet A, Komen J, Manga N, Wolowacz S, Bregantini D, Becker C, Catapano AL. Simulation of long-term impact of bempedoic acid and ezetimibe on atherosclerotic cardiovascular disease outcomes in Europe. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S43. doi: 10.1016/j.jval.2024.10.228
Hohmann C, Manga N, Wolowacz S, Bregantini D, Pfister R. Impact of bempedoic acid on CV outcomes and costs in Germany. Poster presented at the 130th Congress of the German Society of Internal Medicine; April 13, 2024. Wiesbaden, Germany.
Ray KK, Catapano AL, Diamand F, Wolowacz S, Haq I, Bilitou A. Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients. Poster presented at the European Society of Cardiology Congress 2022; August 26, 2022. Barcelona, Spain.
Wilson M, Lim J, Gandhi P, Wang C, Sander S, McDade C, Earnshaw S. Economic analysis of oral anticoagulants in the prevention of vascular events in Medicare patients with nonvalvular atrial fibrillation. Poster presented at the 38th Annual North American Meeting of the Society for Medical Decision Making; October 25, 2016. Vancouver, Canada.
Mauskopf JA, Graham JB, Bae JP, Ramaswamy K, Zagar AJ, Magnuson EA, Cohen DJ, Meadows ES. Cost-effectiveness of prasugrel in a US managed care population. J Med Econ. 2012 Jan 1;15(1):166-74.
Hoogeveen EK, Aalten J, Rothman KJ, Roodnat JI, Mallat MJ, Borm G, Weimar W, Hoitsma AJ, de Fijter JW. Effect of obesity on the outcome of kidney transplantation: a 20-year follow-up. Transplantation. 2011 Apr 27;91(8):869-74.
Meyers JL, Davis KL, Yu Y. ACE inhibitor treatment adjustment and subsequent health care costs among managed care enrollees with hypertension. Poster presented at the Education Conference of the Academy of Managed Care Pharmacies; October 2010.
Earnshaw SR, Wilson M, Mauskopf J, Joshi AV. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Value Health. 2009 Jun 1;12(4):507-20.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty with moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 15, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.
Greene BL, Miller JD, Brown TM, Harshman RS, Richerson GT, Doyle JJ. Economic impact of the BP DownShift Program on blood pressure control among commercial driver license employees. J Occup Environ Med. 2009 May 1;51(5):542-53.
Greene BL, Brown TM, Miller JD, Harshman R, Richerson G, Doyle JJ. Economic impact of the BP downshift program on blood pressure control among commercial driver license employees. Poster presented at the 2008 Academy of Managed Care Pharmacy Educational Conference; October 2008. [abstract] Am J Manag Care. 2008 Oct; 14(7).
Menzin J, Wygant G, Hauch O, Jackel JL, Friedman M. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin. 2008 Feb;24(2):461-8. doi: 10.1185/030079908X261096 .
Earnshaw SR, Wilson MR, Joshi AV. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage over a two-year managed care enrollment period. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. [abstract] Value Health. 2007 May; 10(2):A182. Previously presented at the 2006 International Stroke Conference.
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006 Nov 28;37(11):2751-8.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage. Poster presented at the 2006 International Stroke Conference; February 17, 2006. [abstract] Stroke. 2006 Nov; 37(11):2751.
Earnshaw SR, Wilson MR, Joshi AV. Budgetary impact analysis of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US health plan perspective. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A329.
Earnshaw SR, Wilson MR, Joshi AV. Short-term cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Value Health. 2006 May 1;9(3):A8.
Earnshaw SR, Joshi AV, Wilson MR. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US managed care perspective. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 7, 2006.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.
Pignone M, Earnshaw S, Tice JA, Pletcher M, Wilson M. Aspirin, statins, or both therapies for primary prevention of myccardial infarction: a cost-utility analysis. J Gen Intern Med. 2004 Jan 1;19:121.
Beard SM, Gaffney L, Backhouse ME. An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. J Med Econ. 2001 Jan 1;4:199-205.
Neighbors D, Buckingham T, Greiner W, Schulenburg J. Potential cost savings of the 4 French infiniti catheter in diagnostic coronary angiography. Poster presented at the Inaugural European Congress of the International Society for Pharmacoeconomics and Outcomes Research; December 1998. Cologne, Germany. [abstract] Value Health. 1999 Jan; 2(1):25. doi: 10.1016/S1098-3015(11)70103-6
Zarkin GA, Bala MV, Calingaert B, VanderLugt JT. The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythm. Am J Manag Care. 1997 Jan 1;3(9):1387-94.